News
BIOIO's MOAT platform helps elucidate an understudied protein, TMEM178, connection to NLRP3 and inflammation.
These findings are relevant to BIOIO-2001, which targets SPT to lower deoxy-sphingolipids in diabetic neuropathy. This was a collaboration with University Hospital Zurich.
BIOIO validates its in silico Gene2Drug MOAT module in models of Rheumatoid arthritis. MOAT identified a chemical mimic of IKBz inhibition (Pubmed: 39279148).
BIOIO adds Ildiko Lingvay, MD, a pioneering clinical trialist for the GLP-1 RAs and Professor at Univ. of Texas Southwestern to its Scientific Advisory Board.
Missouri Technology Corporation, a for-profit public private partnership awarded BIOIO seed funding in its January 2024 investment cycle.
BIOIO-2001 was funded by VitaDAO using Molecule’s IP-NFT framework.
